ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Efficacy of Triptolide in Preventing Diabetic Kidney Diseases: A Systematic Review and Meta-Analysis

Liang, Dongning; Mai, Hanwen; Ruan, Fangyi; Fu, Haiyan*南方医科大学; 1
Frontiers in Pharmacology2021-10-1DOI: 10.3389/fphar.2021.728758
7被引21阅读
引用收藏
分享

摘要

Ethnopharmacological Relevance: Triptolide (TP), the primary biologically active ingredient of Tripterygium wilfordii Hook F (TWHF), possesses the potential to solve the shortcomings of TWHF in treating diabetic kidney disease (DKD) in the clinic. @@@ Aim of the Study: We conducted a meta-analysis to evaluate the efficacy of TP in treating DKD and offer solid evidence for further clinical applications of TP. @@@ Materials and Methods: Eight databases (CNKI, VIP, CBM, WanFang, PubMed, Web of Science, EMBASE, and Cochrane library) were electronically searched for eligible studies until October 17, 2020. We selected animal experimental studies using TP versus renin-angiotensin system inhibitors or nonfunctional liquids to treat DKD by following the inclusion and exclusion criteria. Two researchers independently extracted data from the included studies and assessed the risk of bias with the Systematic Review Centre for Laboratory Animal Experimentation Risk of Bias tool. Fixed-effects meta-analyses, subgroup analyses, and meta-regression were conducted using RevMan 5.3 software. Inplasy registration number: INPLASY2020100042. @@@ Results: Twenty-six studies were included. Meta-analysis showed that TP significantly reduced albuminuria (14 studies; standardized mean difference SMD: -1.44 [-1.65, -1.23], I-2 = 87%), urine albumin/urine creatinine ratio (UACR) (8 studies; SMD: -5.03 [-5.74, -4.33], I-2 = 84%), total proteinuria (4 studies; SMD: -3.12 [-3.75, -2.49], I-2 = 0%), serum creatinine (18 studies; SMD: -0.30 [-0.49, -0.12], I-2 = 76%), and blood urea nitrogen (12 studies; SMD: -0.40 [-0.60, -0.20], I-2 value = 55%) in DKD animals, compared to the vehicle control. However, on comparing TP to the renin-angiotensin system (RAS) inhibitors in DKD treatment, there was no marked difference in ameliorating albuminuria (3 studies; SMD: -0.35 [-0.72, 0.02], I-2 = 41%), serum creatinine (3 studies; SMD: -0.07 [-0.62, 0.48], I-2 = 10%), and blood urea nitrogen (2 studies; SMD: -0.35 [-0.97, 0.28], I-2 = 0%). Of note, TP exhibited higher capacities in reducing UACR (2 studies; SMD: -0.66 [-1.31, -0.01], I-2 = 0%) and total proteinuria (2 studies; SMD: -1.18 [-1.86, -2049], I-2 = 0%). Meta-regression implicated that the efficacy of TP in reducing DKD albuminuria was associated with applied dosages. In addition, publication bias has not been detected on attenuating albuminuria between TP and RAS inhibitors after the diagnosis of DKD. @@@ Systematic Review Registration:https://clinicaltrials.gov/, identifier INPLASY2020100042

学科与关键词

关键词
triptoliderenin-angiotensin system inhibitordiabetic kidney diseasesalbuminuriakidney function
相关
加载中…
  • Renal-protective effects of Chinese medicinal herbs and compounds for diabetic kidney disease in animal models: protocol for systematic review and meta-analysis
    Liu, Meifang; Di, Yuan Ming; Zhang, Anthony Lin; Chen, Junhui; Wang, Ruobing; Huang, Juan; Zhang, Lei; Xue, Charlie Changli*; Liu, Xusheng*Systematic Reviews, 2024, 13(1): 23.
  • Effectiveness comparisons of traditional Chinese medicine on treating diabetic nephropathy proteinuria: A systematic review and meta-analysis.
    Wang, Lin; Wang, Ya-Hui; Zhang, Xian-Hui; Yang, Xue-Lian; Wei, Hui-Li; An, Zhi-Chao; Yu, Bo-Rui; Du, Da-Qing; Guo, Yan; Liu, Hong-FangMedicine (Baltimore), 2019, 98(43): e17495.
  • Oral Chinese patent medicines for diabetic kidney disease: An overview of systematic reviews
    Xue, Xue; Li, Ke-ying; Liu, Shang-zhi; Li, Jia-xuan; Jin, Xin-yan; Liu, Xue-han; Lin, La-mei; Zou, Xin-rong; Lu, Chun-li; Zhao, Fang-fang; Liu, Jian-ping*; Wang, Xiao-qin*European Journal of Integrative Medicine, 2023, 61: 102269.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2021-10-01
卷期
第 12 卷
页码
728758
DOI
10.3389/fphar.2021.728758
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81970587, 81770737]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR110104001, 2018GZR0201003]; College Students Innovative Entrepreneurial Training Plan Program [S201912121084]; Outstanding Youths Development Scheme of Nanfang Hospital [2015J006]; Southern Medical University [2020JQPY004]

作者

  • L

    Liang, Dongning (第一作者)

    southern med univ · 1

  • M

    Mai, Hanwen

    southern med univ · 1

查看全部 4 位作者收起作者
  • R

    Ruan, Fangyi

    southern med univ · 1

  • F

    Fu, Haiyan (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417